Sign In
Buy NVTA
$0.0190
+0 (+0%)
At Close: May 13, 2024
Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
11:10am, Thursday, 14'th Aug 2025
SAN FRANCISCO , Aug. 14, 2025 /PRNewswire/ -- Citizen Health, a patient-powered platform transforming rare disease care, announced today it has raised $30 million in Series A funding. The round was le
Labcorp Finalizes Acquisition of Select Assets of Invitae
07:00am, Monday, 05'th Aug 2024
Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C. , Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and c
Labcorp Announces 2024 Second Quarter Results
06:57am, Thursday, 01'st Aug 2024
Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94
Invitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy Patients
07:30am, Monday, 22'nd Jul 2024
– Program provides accessible and affordable testing for pediatric epilepsy patients – – Genetic and clinical insights from test results to strengthen Invitae's rare disease database – SAN FRA
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln
10:25pm, Wednesday, 24'th Apr 2024
Laboratory service provider Labcorp said on Wednesday it will acquire Softbank-backed Invitae Corp's assets auctioned through a voluntary bankruptcy protection process, a few months after the genetic
Labcorp Announces Winning Bid for Select Assets of Invitae
09:27pm, Wednesday, 24'th Apr 2024
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N
Invitae Enters into Agreement with Labcorp for Sale of Business
09:19pm, Wednesday, 24'th Apr 2024
– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Compan
Invitae Publishes its Environmental, Social and Governance (ESG) Report
12:43pm, Monday, 22'nd Apr 2024
– Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
11:30am, Thursday, 11'th Apr 2024
– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics c
Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
07:30am, Tuesday, 12'th Mar 2024
– An Invitae-developed innovative approach to help reduce variants of uncertain significance – SAN FRANCISCO , March 12, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics co
Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
07:15am, Wednesday, 06'th Mar 2024
SAN FRANCISCO , March 6, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit an
Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting
07:30am, Tuesday, 05'th Mar 2024
– Announcing Invitae Generation™, a high-quality variant detection and classification platform – SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading med
Genetic test maker Invitae files for bankruptcy protection in US
11:07pm, Tuesday, 13'th Feb 2024
Softbank-backed genetic test maker Invitae said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy court and intends to pursue a sale process.
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
10:07pm, Tuesday, 13'th Feb 2024
– Company to Use its Cash on Hand to Operate its Business During the Proceedings and Continues to Serve Customers and Patients – SAN FRANCISCO , Feb. 13, 2024 /PRNewswire/ -- Invitae (OTC: NVTA)
The New York Stock Exchange Will Start Delisting Invitae (NVTA) Stock
11:06am, Tuesday, 06'th Feb 2024
Yesterday, shares of Invitae (NYSE: NVTA ) stock plummeted lower by over 75% after The Wall Street Journal reported that the genetic testing services company was preparing for bankruptcy. Invitae has
